Biogen Idec BIIB reported stronger-than-expected results for the third quarter and raised its earnings forecast for the full year.
The Cambridge, Massachusetts-based company posted quarterly net earnings of $856.9 million, or $3.62 per share, compared to $487.6 million, or $2.05 per share, in the year-ago period. Excluding non-recurring items, the company earned $3.80 per share.
Its revenue surged to $2.51 billion versus $1.83 billion. However, analysts were expecting earnings of $3.46 per share on revenue of $2.48 billion.
TECFIDERA revenue during the quarter came in at $787 million, while Interferon revenue came in at $745 million. TYSABRI revenue came in at $501 million in the quarter. ALPROLIX revenue was $25 million in the quarter, while ELOCTATE revenue came in at $22 million.
“The third quarter was a period of significant achievement as we continued to make progress against our corporate objectives,” said Chief Executive Officer George A. Scangos, Ph.D.
Biogen now expects full-year adjusted earnings of $13.45 to $13.55 per share, versus its earlier outlook of $12.90 to $13.10 per share.
Biogen Idec shares declined 0.24% to $326.00 in pre-market trading.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in